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Lazaroids are a group of 21-aminosteroids that lack 
steroid action but have a potent cytoprotective effect 
by inhibiting iron-dependent lipid peroxidation. How-
ever, there have been conflicting reports on the effec-
tiveness and potency of the various lazaroid com-
pounds. In this study, we compared the effectiveness 
of three major lazaroids on warm liver ischemia in 
dogs using a 2-hr hepatic vascular exclusion model. 
The agents were given to the animals intravenously 
for 30 min before ischemia. The animals were divided 
into 5 groups: Control (n=10), no treatment; Group F 
(n=6), U-74006F (10 mg/kg); Group G (n=6), U-74389G 
(10 mg/kg); Group Al (n=6), U-74500A (10 mg/kg); 
Group A2 (n=6), U-74500A (5 mg/kg). The effect of 
treatment was evaluated by two-week animal survival, 
hepatic tissue blood flow, liver function tests, blood 
and tissue biochemistry, and histological analyses. An-
imal survival in all treated groups was significantly 
improved compared with the control (83-100% versus 
30%). Elevation of liver enzymes after reperfusion was 
markedly attenuated in treated groups, except for an 
early significant increase in Group G. Postreperfusion 
hepatic tissue blood flow was much higher in all 
treated animals (50% of the preischemic level vs. 25% 
in the control). Lazaroids, particularly U-74500A at 5 
mg/kg (Group A2), suppressed adenine nucleotide deg-
radation during ischemia and enhanced the resynthe-
sis of high-energy phosphates after reperfusion. Al-
though structural abnormalities in postreperfusion 
liver tissues were markedly ameliorated in all treated 
groups, Group A2 showed significantly less neutrophil 
infiltration. Liver injury from warm ischemia and 
reperfusion was attenuated with all lazaroid com-
pounds, of which U-74500A at 5 mg/kg exhibited the 
most significant protective activity. 
Lazaroids, 21-aminosteroids lacking the negative aspect of 
steroid activity, have cytoprotective properties against iron-
dependent lipid peroxidation (1). In addition to antioxidant 
properties, lazaroids also exert their cytoprotective affect by 
inhibition of arachidonic acid release (1), stabilization of cell 
membranes (2), suppression of Kupffer cell activation (3), 
and down-regulation of cytokine expression and release (4, 
5). The efficacy oflazaroids in preventing ischemia and reper-
fusion injury or extending organ preservation for various 
organs and animal species has been reported by us (6) and 
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others (7-9). However, there have been conflicting reports on 
the potency ofthe various lazaroid compounds (10-12). Three 
major lazaroid compounds, U-74006F, U-74389G, and 
U-74500A were tested in this study to determine which was 
the most effective in abating ischemia and reperfusion injury 
of canine livers subjected to 2-hr of warm ischemia using a 
total hepatic vascular exclusion model. 
MATERIALS AND METHODS 
Animals. Adult female beagle dogs, weighing 8.0 to 12.8 kg, were 
used for this study. The experiment was performed with the approval 
of the Animal Care and Use Committee of the University of Pitts-
burgh, and were managed in accordance with guidelines issued by 
the National Institutes of Health and the Public Health Service 
Policy on the humane use and care of laboratory animals. After an 
overnight fast, the animals were anesthetized with 25 mglkg of 
intravenous thiopental-sodium (Abbott Laboratories, North Chicago, 
IL), intubated, and maintained with a mixture ofisoflurane, oxygen, 
and nitrous oxide by positive mechanical ventilation. The right ca-
rotid artery and the right jugular vein were cannulated for monitor-
ing of arterial blood pressure and central venous pressure, and for 
serial blood sampling. Electrocardiogram, arterial blood gas, electro-
lytes, and esophageal temperature were also monitored throughout 
the operation. 
Operative procedures. Through a midline incision, the liver was 
completely skeletonized by dividing all the hepatic suspensory liga-
ments and by dissecting the retrohepatic vena cava from the poste-
rior abdominal wall. Before starting total hepatic venous exclusion, 
venovenous bypass (Biomedicus, Minetonka, MN), connecting the 
femoral vein, the splenic vein and the left jugular vein via Tygon 
tubing (Norton Industrial Plastics, Akron, OH), was used to decom-
press the splanchnic venous beds and the infrahepatic vena cava. 
Heparin sodium (Upjohn, Kalamazoo, MI), 50 U/kg, was adminis-
tered intravenously 5 min before hepatic ischemia to prevent throm-
bus formation. Ischemia was begun by totally excluding the vascu-
lature of the liver. This was accomplished by cross-clamping the 
portal vein and the hepatic artery (together with the hepatoduodenal 
ligament) and the inferior vena cava above and below the liver. Total 
hepatic vascular exclusion was maintained for 2 hr, after which 
ischemia was stopped by opening the clamps and removing the 
bypass system. A splenectomy was performed immediately after the 
ischemic period. 
During the operation, an electrolyte solution (Plasmalyte, Baxter, 
Deerfield, IL) was continuously infused to the animals at a rate of 20 
ml/kg/hr. Sodium bicarbonate and dopamine hydrochloride were 
given, if necessary, to maintain base excess above -3.0 and systolic 
blood pressure above 90 mmHg. Cephamandole nafate (1 g) was 
given intraoperatively, and continued daily for 3 days. Animals were 
allowed to eat and drink from the next morning. 
Experimental groups. The lazaroid compounds and citrate buffer 
(pH 3.0) were supplied by the Upjohn Company (Kalamazoo, MI). 
The lazaroids were dissolved in the citrate buffer vehicle at a con-
centration of 1.5 mg/ml with U-74006F, and at 2 mg/ml with 
U-74389G and U-74500A. Animals were divided into five groups: 
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Control (n=10, no treatment), Group F (n=6, 10 mg/kg ofU-74006F), 
Group G (n=6, 10 mg/kg ofU-74389G), Group Al (n=6, 10 mg/kg of 
U-74500A), and Group A2 (n=6, 5 mg/kg of U-74500A). Lazaroids 
were given as a continuous intravenous infusion for 30 min before 
ischemia. Animals were followed for two weeks after liver ischemia. 
Determinations. The cytoprotective effect of the respective laz-
aroid compound was studied using the following determinants: two-
week animal survival, liver function tests, hepatic tissue blood flow, 
blood and tissue biochemistry, and histological analyses. 
Indocyanine green retention test: The effectiveness of hepatic 
vascular exclusion was determined using the indocyanine green 
(ICG)* retention test. Indocyanine green (lCG, Cardio-Green, Beck-
ton Dickinson Microbiology Systems, Cockeysville, MD) at a dose of 
0.5 mg/kg, was intravenously administered 30 min after the onset of 
total hepatic venous exclusion, and 3 ml of heparinized arterial blood 
was collected 20 min after ICG injection. Indocyanine green reten-
tion rate was determined using a spectrophotometer (Lamda, Perkin 
Elmer, Norwalk, CT) at a wavelength of 805 nm. 
Hepatic tissue blood flow: Tissue blood flow, at the hepatic sur-
face, was measured using a laser-Doppler flow meter (Advance laser 
flowmeter, ALF21, Advance Company Ltd., Tokyo, Japan) before 
ischemia, during ischemia, and 5 min, 15 min, 30 min, and 60 min 
after reperfusion. Tissue blood flow was calculated as the mean flow 
of the right hepatic lobe, the middle hepatic lobe, and the left hepatic 
lobe. Tissue flow is expressed as a percentage of the preischemic 
level. 
Liver function tests: Blood samples for liver function tests were 
collected before ischemia, after 2 hr of ischemia, and 15 min, 60 min, 
3 hr, 6 hr, 12 hr, 24 hr, 2 days, 3 days, 5 days, 7 days, 10 days, and 
14 days postischemia. A Technicon RA500 autoanalyzer (Bayer, Tar-
rytown, NY) was used to determine plasma levels of aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), lactate dehy-
drogenase (LDH), alkaline phosphatase (ALP), and total bilirubin. 
Plasma malondialdehyde: Heparinized arterial blood samples 
were collected before ischemia, at the end of ischemia, and 15 min 
and 60 min after reperfusion. Plasma malondialdehyde levels were 
measured according to the method by Yagi (13). 
Tissue biochemistry: A small wedge biopsy was taken from the 
liver before ischemia, 1 hr and 2 hr after onset of ischemia, and 15 
min and 60 min after reperfusion. The tissue samples were immedi-
ately (5-10 sees) frozen in liquid nitrogen and stored at -80°C until 
analysis. Tissue concentrations of adenine nucleotides (AN) and 
purine catabolites (PC) were measured using a Waters HPLC system 
(Waters Chromatography Division, Millipore Corp., Milford, MA; 
Model 510 pumps, Model 484 absorbance module, and Model 717 
WISP system), equipped with a tunable absorbance detector (Waters 
Model 484). Energy charge (EC) was calculated using the equation 
(14) ATP+0.5 ADP/(ATP+ADP+AMP). 
Histopathology: A small portion of each tissue taken for tissue 
biochemistry was fixed in buffered formalin, paraffin-embedded and 
stained with hematoxylin eosin. Histopathologic changes were 
blindly read by a single pathologist. Neutrophil inmtration was 
determined by taking the mean count made in twenty randomly 
selected observation fields (at a magnification of 100X) of each sec-
tion/animal after neutrophil staining by Leder's method. 
Statistics. Values are expressed as mean::': SEM. Animal survival 
was determined using the chi-square test. Intragroup analysis was 
performed using the paired Student's t test. Intergroup analysis was 
performed using ANOV A. When the analysis of variance showed a 
* Abbreviations: ADP, adenosine diphosphate; ALP, alkaline 
phosphatase; ALT, alanine aminotransferase; AMP, adenosine 
monophosphate; AN, adenine nucleotides; AST, aspartate amino-
transferase; ATP, adenosine triphosphate; EC, energy charge; ICG, 
indocyanine green; LDH, lactate dehydrogenase; MAP, mean arte-
rial pressure; MDA, plasma malondialdehyde; PC, purine catabo-
lites; POD, postoperative day. 
significant difference (P<0.05), a post hoc test was used to determine 
the P values for each group. 
RESULTS 
Clinical observations. Although mean arterial blood pres-
sure (MAP) of the Control dogs showed a slight decline soon 
after initiating hepatic venous exclusion (from 113.25::':6.01 
mmHg to 95.05::':8.46 mmHg), the MAP remained relatively 
stable (> 100 mmHg) during liver ischemia, with a mean 
bypass flow of 0.85::':0.05 Umin. After reperfusion, however, 
all animals developed hypotension (52.11::':5.65 mmHg at 5 
min after reperfusion). The blood pressure gradually recov-
ered to preoperative levels 3 hr after reperfusion. During the 
30 min intravenous drug infusion, U-74006F and U-74389G 
caused no significant hemodynamic changes, but moderate 
and significant hypotension occurred in Group Al animals, 
with 4 animals developing arrhythmia. Decrease of the 
U-74500A dose from 10 mg/kg (Group AI) to 5 mg/kg (Group 
A2) abrogated hypotension and arrhythmia. 
Liver revascularization in the control animals was charac-
terized by severe swelling, mottled reperfusion, and a palpa-
bly hard liver, all indicating an outflow block. These charac-
teristics were seen in only one animal of Group F and Group 
G, and none in Group Al or Group A2. 
lCG retention rate. The completeness of hepatic venous 
exclusion was confirmed by ICG retention rate. Indocyanine 
green retention rate during liver ischemia was 94.82::':1.26% 
in the controls, 96.61::':2.64% in Group F, 95.18::':0.69% in 
Group G, 96.02::':1.77% in Group AI, and 95.98::':1.83% in 
Group A2. There were no significant differences between the 
groups. 
Survival. Survival of the treated groups was significantly 
better than Control. By the end of the two-week follow-up 
period, seven of ten control animals died from liver failure, 
six on postoperative day (POD) 1 and another on POD 10. In 
contrast, all but one animal in the treated groups survived 
for two weeks; one of the Group F animals died on POD 2 
from bleeding due to an injured splenic vein with normalizing 
liver enzymes. There was no statistically significant differ-
ence in animal survival between lazaroid groups. 
Liver function tests. The LDH of the Control animals re-
mained high for 12 hr after reperfusion (Fig. 1A). Among the 
lazaroid-treated groups, Group G showed a much higher 
elevation in LDH than the Control 15 minutes after reperfu-
sion, while the other three groups had lower LDH levels than 
the Control throughout the observation period. Aspartate 
aminotransferase and ALT (Fig. 1B) of the Control animals 
elevated rapidly after unclamping, reaching the maximal 
values 12 hr after reperfusion. Transaminase levels of Group 
F, Group AI, and Group A2 were significantly lower than the 
Control and Group G during the early postoperative period. 
There was no statistically significant difference in LDH, 
AST, or ALT levels between Groups F, AI, and A2. Two 
animals in the Control group had a total bilirubin level 
greater than 3 mg/dl; one died at POD 1 from liver failure and 
the other lived for 14 days. In the lazaroid groups, hyperbil-
irubinemia was seen in only one Group G animal. 
Hepatic tissue blood flow. During ischemia, hepatic tissue 
blood flow decreased to 10.40::':1.33% of the preischemic level 
in all groups. After reperfusion, restoration of blood flow was 
significantly inhibited in the Control group (23.9::':5.7% 60 
min after reperfusion). However, lazaroid treatment aug-
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FIGURE 1. (A) Changes in lactate dehydrogenase (LDH) after reper-
fusion: * P<O.05 vs. Control, Groups F, AI, A2; ** P<O.05 vs. Groups 
F, AI, A2; # P<O.05 vs. Groups F, G, AI, A2. (B) Changes in alanine 
aminotransferase (ALT) after reperfusion: * P<O.05 vs. Groups F, 
AI, A2; ** P<O.05 vs. Groups F, G, AI, A2. 
mented postreperfusion blood flow to more than 40% in all 
groups. Group A2 showed markedly higher hepatic tissue 
blood flow than the other three lazaroid groups (Fig. 2). 
Plasma MDA levels. There was no significant difference in 
plasma MDA levels between Control and lazaroid groups at 
the end of two-hour liver ischemia (Fig. 3). Reperfusion 
caused a significant increase in MDA in all groups; however, 
the increase in plasma MDA of Group A2 15 and 60 min after 
reperfusion was significantly lower than Control. 
Energy metabolism. Changes in adenine nucleotides and 
purine catabolites, reflecting energy metabolism in the he-
patic tissue, during ischemia and after reperfusion are shown 
in Table 1. Hepatic ischemia induced marked degradation of 
ATP, resulting in higher concentrations of AMP and purine 
catabolites. After reperfusion, energy re-synthesis (estimated 
by energy charge) was poor 15 min after reperfusion, but 
recovered to normal levels at 60 min. Compared to Control, 
ATP degradation during hepatic ischemia was moderately 
suppressed by the treatment with lazaroids. In fact, 
U-74500A at 5 mg/kg (Group A2) showed significantly better 
energy charge, higher adenine nucleotide levels, and less 
accumulation of purine catabolites than Control. In addition, 
Group A2 animals showed a prompt restoration of energy 
charge to normal levels 15 min after reperfusion, while en-
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FIGURE 2. Tissue blood flow in the liver during ischemia and after 
reperfusion. Values are expressed as a percentage of the preischemic 
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FIGURE :3. Changes in plasma malodialdehide (MDA) at the end of 
warm ischemia and after reperfusion. " P<O.05 vs. Control. 
ergy charge of the other three lazaroid groups remained poor. 
As with the Control, energy charge returned to normal levels 
60 min after reperfusion in all lazaroid groups, except for 
Group G. 
Histopathology. The 2-hr total liver ischemia caused no 
remarkable changes in liver structure except for occasional 
single hepatocyte necrosis that was seen equally in all 
groups. Although the basic architecture was preserved, Con-
trollivers developed marked abnormalities after reperfusion, 
such as centrilobular hepatocyte necrosis, ballooning, degen-
eration, and hemorrhagic congestion (Fig. 4A). Detachment 
of sinusoidal cells was found frequently in the vicinity of 
necrotic areas, accompanied by intense neutrophil infiltra-
tion. Lazaroids prevented sinusoidal congestion and inhib-
ited hepatocyte necroses and ballooning. Only a few neutro-
phils were seen in a scattered area (Fig. 4B). In comparing 
neutrophil infiltration 60 min after reperfusion, the number 
counted in Group A2 was significantly less than all other 
groups (Fig. 5). 
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FIGURE 4. (A) Control gTOUp liver tissue 60 min after reperfusion. 
Hepatocytes necrosis and vacuolation were found at pericentral area 
and other scattered areas. Hemorrhage and sinusoidal congestion 
were found at the site of parenchymal necrosis. Parenchymal dam-
age was associated with neutrophil infiltration. (H&E; x200). (B) 
Group A2 liver tissue 60 min after reperfusion. Liver architecture 
was well preserved. Liver parenchymal damage was not significant, 
with only single cell necrosis or vacuolation. Hemorrhage and sinu-
soidal congestion were rare. Neutrophil infiltration was reduced 
compared to Control. (H&E; x 200). 
DISCUSSION 
This study showed that prolonged hepatic warm ischemia 
causes severe liver damage and high mortality in control 
animals. In contrast, administration of lazaroid compounds 
before ischemia attenuated ischemic liver damage and im-
proved animal survival. In addition , we showed that 
U-74500A, at a dose of 5 mg/kg, was most effective compared 
to the other lazaroid compounds, allowing better hepatic 
tissue blood flow, lower liver enzyme elevation, improved 
energy metabolism, less lipid peroxidation, and reduced neu-
trophil accumulation. 
In this study, we used a total hepatic vascular exclusion 
model to examine the effectiveness of lazaroids against liver 
ischemia. Most previous studies of warm liver ischemia and 
reperfusion have used Pringle's maneuver (15, 16), which 
interrupts the hepatic blood in-flow at the hepatic hilum. 
When the mesenteric venous beds are appropriately decom-
pressed by a passive or pump-driven portasystemic bypass 
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FIGURE 5. Number of neutrophils in the liver 60 min after reperfu-
sion: " P<0.05 vs . Control, Groups F, G, A1; ** Average numbers in 
10 power fields (X100). 
(17), dogs have been shown to tolerate liver ischemia for 60 
min (18), 90 min (19), or 180 min (17). The total hepatic 
vascular exclusion model causes more severe liver ischemia 
than the Pringle's maneuver, due to the almost total absence 
of hepatic blood flow. While the Pringle's maneuver occludes 
only the portal vein and hepatic artery, total hepatic vascular 
exclusion also occludes the infrahepatic and suprahepatic 
vena cava. The effectiveness of the total hepatic vascular 
exclusion model was confirmed by measuring the leG reten-
tion rate, which was more than 95% during ischemia. Using 
the total hepatic vascular exclusion model, we first showed 
that 30% of the control dogs could tolerate two hours of 
hepatic warm ischemia. This result is in direct contrast to 
other reports (20,21) showing mortality in all animals sub-
jected to 60 min of hepatic vascular exclusion. The animal 
strain and perioperative management, including careful 
maintenance of bypass flow and fluid and electrolyte balance, 
might be responsible for the difference in results. 
There appeared to be significant differences in the effec-
tiveness of the three lazaroid compounds at the same 10 
mg/kg dose. The 10 mg/kg dose was selected based on our 
previous study, in which 10 mg/kg of intravenous U-74389G 
administered to the donors 30 min before procurement was 
more effective than doses of 6 mg/kg or 15 mg/kg in 48-hr 
canine liver preservation and transplantation. At the 10 
mg/kg dose, U-74500A was more effective than U-74006F 
and U-74389G. Group G had much higher liver enzymes 
during the early postoperative period compared with Group 
A and Group F. Lazaroid U-74500A significantly reduced 
accumulation of purine catabolites in the ischemic liver tis-
sue, and enhanced hepatic tissue blood flow after reperfusion 
compared with Lazaroid F. In addition, when the dose of 
U-74500A was decreased to 5 mg/kg (Group A2), it not only 
eliminated cardiovascular adverse effects that were fre-
quently seen with 10 mg/kg ofU-74500A (Group AI), but also 
allowed better hepatic tissue blood flow, less MDA produc-
tion, prompt energy resynthesis, and better hepatic structure 
than Group Al animals . The different protective activity 
between Groups Al and A2 may result from aU-shaped 
dose-dependent effectiveness (22), which seems to be inher-
ent to the lazaroid compounds. This U-shaped dose-response 
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curve was observed in this study and in our previous liver 
preservation experiment with U-74389G (6). 
The differing potency of lazaroids determined in our exper-
iment may be related to the site of action of the respective 
agents in the lipid peroxidation cascade. Lipid peroxidation is 
caused by oxygen radicals, which are generated as superox-
ide anions by the conversion of hypoxanthine to xanthine 
during reoxygenation. Mitochondrial oxidative phosphoryla-
tion, arachidonic acid metabolism, and the NADPH-depen-
dent oxidase system on the surface membrane ofneutrophils 
are other sources of superoxide radical generation. Once gen-
erated, superoxide anions propagate to produce hydroxyl rad-
icals by Haber-Weiss reaction and Fenton reduction with 
participation offerrous iron. Hydroxyl radicals attack unsat-
urated fatty acids to form lipid peroxyl radicals, which pro-
ceeds to a radical-driven chain reaction causing more peroxi-
dation of unsaturated fatty acids. Although all three lazaroid 
compounds are potent antioxidants, U-74500A is 2-10 times 
more effective in inhibiting iron-dependent lipid peroxida-
tion, by chelating iron, than U-74006F (23)- however, 
U-74006F and U-78517G are more effective in scavenging 
lipid peroxyl radicals (like alpha-tocopherol) than U-74500A 
(1, 24). Thus, the potency of U-74500A, as shown in our 
experiment, might indicate that early inhibition of lipid per-
oxidation by iron chelation is more beneficial than scaveng-
ing lipid peroxyl radicals that have already formed. Killinger 
et al. (25) reported that U-74500A was more potent than 
U-75412E and U-74006F for preservation of endothelial cell 
viability in tissue culture and cold storage. 
At aerobic conditions, cellular function is regulated by the 
level of high-energy phosphate (ATP) produced exclusively by 
oxidative phosphorylation in the mitochondria. When tissue 
becomes ischemic, ATP is progressively degradated to other 
adenine nucleotides, nucleosides, and finally, purine catabo-
lites. Levels of ATP are restored after reoxygenation via the 
salvage pathway and through the slow, but more efficient, 
pathway of de novo synthesis. Pre-ischemic treatment with 
lazaroids, particularly U -7 4500A, slowed ATP degradation, 
suppressed PC accumulation, and enhanced ATP resynthe-
sis. Although the mechanism is unclear, the beneficial effect 
of lazaroids in ischemic and postischemic energy metabolism 
appears to be related to their antioxidant activity. While 
most studies of lipid peroxidation have focused on events 
after reoxygenation, only a few studies have examined the 
events occurring during ischemia, and these have revealed 
that lipid peroxidation also occurs to some extent during 
ischemia (19,26). Once cellular membranes are damaged by 
free radicals attack during ischemia, they become leaky to 
constitutes of adenine nucleotides (27). The adenine nucleo-
tides are converted to nucleosides in the interstitial space, 
and taken up by endothelial cells (28), where they are catab-
olized to hypoxanthine. Since sinusoidal endothelial cells are 
abundant in xanthine oxidase (29), they may be more vulner-
able to oxygen radicals generated by the xanthine oxidase 
system when the blood supply is restored. It has been previ-
ously shown in rat livers that lipid peroxidation occurs in the 
endothelial cells during warm ischemia (30). Endothelial cell 
protection should lead to the preservation of the hepatic 
microcirculation. The early resumption of energy metabolism 
and higher tissue blood flow associated with lazaroid treat-
ment in this study, and as described previously by us (6) and 
others (7, 8), suggests that lazaroids protect not only the 
parenchymal hepatocytes, but the sinusoidal endothelial 
cells as well. 
There is a growing body of evidence demonstrating that 
neutrophils are vigorously involved in ischemia and reperfu-
sion injury of organs. Neutrophil depletion and the adminis-
tration of antineutrophil serum or antineutrophil monoclonal 
antibody significantly reduced damage in the heart (31), liver 
(32), and small bowel (33). Neutrophils accumulate, adhere, 
and are activated in postischemic liver tissues under the 
regulation of cytokines, chemotactic factors, and adhesion 
molecules that are produced by Kupffer cells, endothelial 
cells, hepatocytes, and inflammatory cells in the liver. Mter 
reperfusion, activated Kupffer cells produce inflammatory 
cytokines, interleukin-l and tumor necrosis factor, that acti-
vate endothelial cells and neutrophils. These cytokines, as 
well as leukotriene and platelet activating factor produced 
via arachidonic acid metabolism, have a chemotactic prop-
erty for neutrophils. In addition, the cytokines upregulate 
expression of adhesion molecules on the surface of neutro-
phils to facilitate their rolling, adhesion, and activation. Ac-
tivated neutrophils not only generate superoxide anions but 
also release myeloperoxidase and elastase, which further 
augment the destruction ofliver tissues. Lazaroids have been 
shown to interrupt the chain of the inflammatory cascade 
that leads to neutrophil activation by affecting Kupffer cells 
(3) and cytokines (4), leukotrienes (34), oxygen radicals (35), 
and neutrophil enzymes (34). In the present study, U-74500A 
at 5 mg/kg showed less neutrophil infiltration in postisch-
emic liver tissues. 
In conclusion, lazaroids are cytoprotective to the canine 
liver during 2 hr of warm liver ischemia. Lazaroid U-74500A 
at a dose of 5 mg/kg was found most effective. Although 
lazaroids are very effective in the amelioration of ischemia 
organ damage, the hydrophobic nature of the compounds 
may limit their practical applicability. One solution would be 
the development of a new agent that has similarly potent 
antioxidant activity with hydrophilic properties, allowing 
oral administration and dissolution in the organ preservation 
fluid, which is currently underway. 
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